Status:
COMPLETED
Post Marketing Surveillance of MENOPUR
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Infertility
Eligibility:
FEMALE
18+ years
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of highly purified (HP) menotrophine to Korean women.
Eligibility Criteria
Inclusion
- Anovulation in women (WHO group II)
- Controlled ovarian hyperstimulation cases for ART
Exclusion
- Hypersensitivity to MENOPUR
- Pregnancy, lactation or contraindication to pregnancy
- Ovarian cysts not related to polycystic ovarian syndrome
- Abnormal uterine bleeding
- Tumors in uterus, ovaries and breasts
- Ovarian hyperstimulation syndrome
- Thromboembolism or history of it
- Infertile due to other reason than anovulation
- High FSH level indication primary ovarian failure
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
2501 Patients enrolled
Trial Details
Trial ID
NCT01202123
Start Date
December 1 2008
End Date
February 1 2014
Last Update
February 21 2014
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Busan Maria hospital
Busan, Busan, South Korea
2
Daegu Maria
Daegu, Daegu, South Korea
3
Daejeon Maria
Daejeon, Daejeon, South Korea
4
Daejeon Seoul Women Hospital
Daejeon, Daejeon, South Korea